Gaviscon, chewable mint pills 48pcs

Composition

of 1 tab.

sodium alginate 250 mg

sodium bicarbonate 133.5 mg

calcium carbonate 80 mg

Auxiliary substances:

mannitol-255 mg,

macrogol 20 000-30 mg,

magnesium stearate-4 mg,

aspartame-3.75 mg,

copovidone-28 mg,

potassium acesulfame-3.75 mg,

mint flavor-12 mg

Pharmacological action

Gaviscone enters the stomach and interacts with its contents, forming a protective barrier (raft) that prevents the occurrence of heartburn.

An antacid drug. After ingestion, the drug quickly interacts with the acidic contents of the stomach. In this case, an alginate gel is formed, which has an almost neutral pH value.

The gel forms a protective barrier on the surface of the stomach contents, preventing the occurrence of gastroesophageal reflux for up to 4 hours. In the case of regurgitation, the gel is more likely to enter the esophagus, where it reduces mucosal irritation.

A decrease in irritation of the esophageal mucosa is felt 3-4 minutes after taking the drug.

Pharmacokinetics

The drug has no systemic bioavailability (it is not absorbed).

Indications

-treatment of symptoms such as acid belching, heartburn, dyspepsia, a feeling of heaviness in the stomach that occur after eating, in patients with gastroesophageal reflux or during pregnancy.

Contraindications

-phenylketonuria; – children under 12 years of age;- hypersensitivity to the components of the drug. With caution, the drug should be used for hypercalcemia, nephrocalcinosis and urolithiasis with the formation of oxalate stones, congestive heart failure, impaired renal function. If these diseases or conditions are present, the patient should consult a doctor before using the drug.

Side effects

The frequency of adverse reactions is estimated based on the following criteria: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10 000, <1/1000), very rare (Immune system disorders: frequency unknown – anaphylactic and anaphylactoid reactions, hypersensitivity reactions (urticaria). Respiratory system disorders: frequency unknown-respiratory effects (bronchospasm). If any of the side effects indicated in the instructions are aggravated or other side effects are noted that are not specified in the instructions, the patient should inform the doctor about this.

Interaction

The drug contains calcium carbonate, which exhibits antacid activity, so at least 2 hours should elapse between taking Gaviscon® and other drugs, especially when used simultaneously with histamine H2-receptor blockers, tetracycline antibiotics, digoxin, fluoroquinolones, iron salts, ketoconazole, neuroleptics, levothyroxine sodium, thyroid hormones, penicillamine, beta-blockers (atenolol, metoprolol, propranolol), corticosteroids, chloroquine, bisphosphonates and estramustine.

How to take, course of use and dosage

The drug is taken orally. The tablet should be chewed thoroughly. Adults and children over 12 years of age are prescribed 2-4 tablets after meals and before bedtime (up to 4 times a day). If symptoms persist after 7 days of using the drug, the patient should consult a doctor to review the therapy. Elderly patients do not need to adjust the dose. No dose adjustment is required in patients with hepatic impairment. In patients with impaired renal function, if a low-salt diet is required, the drug should be taken with caution.

Overdose

Symptoms:  bloating.

Treatment:  conducting symptomatic therapy.

Special instructions

In a dose of 4 tablets, the sodium content is 246 mg, which should be taken into account when it is necessary to follow a diet with a limited salt content (for congestive heart failure, with impaired renal function).

Each dose of 4 tablets contains 320 mg of calcium carbonate. Caution should be exercised when treating patients with hypercalcemia, nephrocalcinosis and urolithiasis with the formation of oxalate stones.

The drug contains aspartame, so it should not be used in patients with phenylketonuria. Since aspartame is a non-specific sweetener, patients with diabetes mellitus can use Gaviscon®.

Influence on the ability to drive motor vehicles and manage mechanisms

The drug does not affect the ability to drive vehicles and mechanisms, as well as to engage in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Form of production

Chewable tablets (mint) from almost white to cream color with small inclusions, round, flat, with beveled edges, with the image of a circle and a sword on one side and the inscription “G 250” on the other, with a mint smell.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 30°C.

Shelf

life is 2 years.

Active ingredient

Sodium Alginate, Sodium Bicarbonate, Calcium Carbonate

Dosage form

tablets for resorption

Description

Nursing mothers, Children over 12 years old, Pregnant women, Adults

Indications

Gastritis, Reflux Esophagitis, Gastric and duodenal ulcers, Heartburn